Risultati della ricerca - Lawrence E. Morris

  • Mostra 1 - 17 risultati su 17
Raffina i risultati
  1. 1
    Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation

    Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood... di Scott R. Solomon, Melissa Sanacore, Xu Zhang, Stacey Brown, Kent Holland, Lawrence E. Morris, Asad Bashey

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center

    Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center di Melhem Solh, Xu Zhang, Katelin Connor, Stacey Brown, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, Asad Bashey

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial

    Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventi... di Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore, Xu Zhang, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Asad Bashey

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors

    Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Match... di Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore, Xu Zhang, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Asad Bashey

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

    T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of... di Asad Bashey, Xu Zhang, Connie A. Sizemore, Karen Manion, Stacey Brown, H. Kent Holland, Lawrence E. Morris, Scott R. Solomon

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index

    Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -D... di Asad Bashey, Xu Zhang, Katelin C Jackson, Stacey Brown, Michelle Ridgeway, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

    Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patient... di Zain Bashey, Xu Zhang, Stacey Brown, Katelin C Jackson, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Scott R. Solomon, Melhem Solh

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

    A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fluda... di Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

    Pubblicazione 2007
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables

    Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables di Scott R. Solomon, Michael T. Aubrey, Xu Zhang, Allison Piluso, Brian M. Freed, Stacey Brown, Katelin C Jackson, Lawrence E. Morris, H. Kent Holland, Melhem Solh, Asad Bashey

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia

    Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia di Steven D. Gore, Ivana Gojo, Mikkael A. Sekeres, Lawrence E. Morris, Marcel P. Devetten, Katarzyna Jamieson, Robert L. Redner, R.J. Arceci, Ibitayo Owoeye, Tianna Dauses, Esther Schachter-Tokarz, Robert E. Gallagher

    Pubblicazione 2010
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

    CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation di Asad Bashey, Bridget Medina, Sue Corringham, Mildred Pasek, Ewa Carrier, Linda Vrooman, Israel Lowy, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, James R. Mason, Edwin P. Alyea, Robert J. Soiffer, Edward D. Ball

    Pubblicazione 2008
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia di Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline M. Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence E. Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett‐Mayer, Peter L. Greenberg, James R. Wright, Judith E. Karp

    Pubblicazione 2006
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial

    Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial di Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent R. Logan, Joseph H. Antin, Peter Dawson, Steven M. Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

    Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome di Yvette L. Kasamon, Leo Luznik, Mary S. Leffell, Jeanne Kowalski, Hua-Ling Tsai, Javier Bolaños‐Meade, Lawrence E. Morris, Pamela Crilley, Paul V. O’Donnell, Nancy Rossiter, Carol Ann Huff, Robert A. Brodsky, William Matsui, Lode J. Swinnen, Ivan Borrello, Jonathan D. Powell, Richard F. Ambinder, Richard J. Jones, Ephraim J. Fuchs

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

    Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial di Joseph Alvarnas, Jennifer Le Rademacher, Yanli Wang, Richard F. Little, Görgün Akpek, Ernesto Ayala, Steven M. Devine, Robert A. Baiocchi, Gerard Lozanski, Lawrence D. Kaplan, Ariela Noy, Uday Popat, Jack W. Hsu, Lawrence E. Morris, Jason Thompson, Mary M. Horowitz, Adam Mendizabal, Alexandra M. Levine, Amrita Krishnan, Stephen J. Forman, Willis H. Navarro, Richard F. Ambinder

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

    The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1... di Andrew Artz, Brent R. Logan, Wael Saber, Nancy L. Geller, Anna Bellach, Jianqun Kou, William A. Wood, John M. McCarty, Thomas G. Knight, Lyndsey Runaas, Laura Johnston, Jeremy Walston, Ryotaro Nakamura, Tammy A. Schuler, Asmita Mishra, Joseph P. Uberti, Parastoo B. Dahi, Jennifer N. Saultz, Shannon R. McCurdy, Lawrence E. Morris, Philip Imus, William J. Hogan, Kalyan Nadiminti, Vijaya Raj Bhatt, Deborah Mattila, Bailey Protz, Steven M. Devine, Mary M. Horowitz, Mohamed L. Sorror

    Pubblicazione 2023
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704

    Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704 di Mohamed L. Sorror, Wael Saber, Brent R. Logan, Nancy L. Geller, Anna Bellach, Jianqun Kou, William A. Wood, John M. McCarty, Thomas G. Knight, Lyndsey Runaas, Laura Johnston, Jeremy Walston, Ryotaro Nakamura, Louise Jarrett, Asmita Mishra, Joseph P. Uberti, Parastoo B. Dahi, Jennifer N. Saultz, Shannon R. McCurdy, Lawrence E. Morris, Philip Imus, William J. Hogan, Kalyan Nadiminti, Vijaya Raj Bhatt, Rebecca L. Olin, Joseph E. Maakaron, Ronald Sobecks, Sarah Wall, Deborah Mattila, Bailey Protz, Steven M. Devine, Mary M. Horowitz, Andrew Artz

    Pubblicazione 2025
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: